Ph.D. Roni Mamluk - 03 Jan 2022 Form 4 Insider Report for Ayala Pharmaceuticals, Inc.

Role
President & CEO, Director
Signature
/s/ Roni Mamluk, Ph.D.
Issuer symbol
N/A
Transactions as of
03 Jan 2022
Net transactions value
$0
Form type
4
Filing time
05 Jan 2022, 15:06:03 UTC
Previous filing
05 Aug 2021
Next filing
16 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AYLA Stock Option Award $0 +127,800 $0.000000 127,800 03 Jan 2022 Common Stock 127,800 $9.10 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests and becomes exercisable in sixteen substantially equal quarterly installments following the grant date, such that the option shall be fully vested on January 3, 2026.